Uzu Takashi, Harada Tamaki, Namba Tomoko, Yamamoto Ryohei, Takahara Ken, Yamauchi Atsushi, Kimura Genjiro
Division of Nephrology, Osaka Rosai Hospital, Sakai, Osaka, Japan.
J Hypertens. 2005 Apr;23(4):861-5. doi: 10.1097/01.hjh.0000163156.37363.47.
We examined whether thiazide diuretics could restore nocturnal blood pressure (BP) decline and reduce urinary protein excretion in patients with glomerulopathy treated with angiotensin II modulators (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers).
Twenty-five Japanese outpatients (11 men, 14 women; mean age 43 +/- 12 years) with biopsy-proven immunoglobulin (Ig)A nephropathy, preserved renal function (serum creatinine concentration </=1.2 mg/dl), stable non-nephrotic proteinuria (0.5-3 g daily), and treatment with angiotensin II modulators were studied. The patients received a diuretic, trichlormethiazide (2 mg daily) for 4 weeks after a baseline period lasting for 4 weeks.
Diuretic therapy significantly reduced conventional, 24-h, daytime and night-time blood pressures. Nocturnal blood pressure fall was significantly enhanced by diuretic therapy and a significant interaction existed between diuretic therapy and nocturnal fall in mean arterial pressure, which indicated that the degree of nocturnal blood pressure fall was affected by diuretic therapy. The urinary protein excretion rate was significantly reduced from 1.10 +/- 0.62 to 0.63 +/- 0.39 g/day by diuretic therapy. Diuretic/baseline ratio of urinary protein excretion rate was not correlated with diuretic/baseline ratio of conventional, 24-h and daytime mean arterial pressures, but with diuretic/baseline ratio of night-time mean arterial pressure (r = 0.54, P = 0.006).
Diuretics enhanced nocturnal BP decline and reduced urinary protein excretion in patients with IgA nephropathy treated with angiotensin II modulators. The combination of angiotensin II modulators and diuretics may have additional therapeutic advantages in relieving the renal and cardiovascular risks by reducing nocturnal high blood pressure.
我们研究了噻嗪类利尿剂是否能恢复接受血管紧张素II调节剂(血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂)治疗的肾小球病患者的夜间血压下降,并减少尿蛋白排泄。
对25名日本门诊患者(11名男性,14名女性;平均年龄43±12岁)进行研究,这些患者经活检证实患有免疫球蛋白(Ig)A肾病,肾功能 preserved(血清肌酐浓度≤1.2mg/dl),稳定的非肾病性蛋白尿(每日0.5 - 3g),且正在接受血管紧张素II调节剂治疗。在为期4周的基线期后,患者接受利尿剂三氯噻嗪(每日2mg)治疗4周。
利尿剂治疗显著降低了常规、24小时、日间和夜间血压。利尿剂治疗显著增强了夜间血压下降,且利尿剂治疗与平均动脉压的夜间下降之间存在显著交互作用,这表明夜间血压下降程度受利尿剂治疗影响。利尿剂治疗使尿蛋白排泄率从1.10±0.62g/天显著降低至0.63±0.39g/天。尿蛋白排泄率的利尿剂/基线比值与常规、24小时和日间平均动脉压的利尿剂/基线比值无关,但与夜间平均动脉压的利尿剂/基线比值相关(r = 0.54,P = 0.006)。
利尿剂增强了接受血管紧张素II调节剂治疗的IgA肾病患者的夜间血压下降并减少了尿蛋白排泄。血管紧张素II调节剂与利尿剂联合使用可能在通过降低夜间高血压来缓解肾脏和心血管风险方面具有额外的治疗优势。